![Ilan Oren](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ilan Oren
Presidente presso
ROIVANT SCIENCES LTD.
Patrimonio netto: 4 M $ in data 31/08/2026
Profilo
Ilan Oren is Co-Chief Executive Officer at Dexcel Pharma Technologies Ltd. since 2019 and Co-CEO at Dexcel Ltd. Mr. Oren is Independent Chairman at Roivant Sciences Ltd. since 2023 and Director at Roivant Sciences, Inc. Mr. Oren is Director at Clexio Biosciences Ltd. since 2018, Director at Kriya Therapeutics, Inc. since 2020, and Director at 8400 - The Health Network since 2019.
Former roles include Independent Director at Cynapsus Therapeutics, Inc. from 2014 to 2016, Director at Sio Gene Therapies, Inc. from 2018 to 2020, Non-Executive Director at Sio Gene Therapies, Inc. from 2015 to 2017, and Independent Director at Montes Archimedes Acquisition Corp.
Education includes undergraduate studies at Harvard College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/07/2026 | 121.004 ( 0,02% ) | 4 M $ | 31/08/2026 |
Posizioni attive di Ilan Oren
| Società | Posizione | Inizio |
|---|---|---|
| ROIVANT SCIENCES LTD. | Presidente | 13/03/2023 |
Dexcel Pharma Technologies Ltd.
 Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Amministratore Delegato | 01/11/2019 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Direttore/Membro del Consiglio | - |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Direttore/Membro del Consiglio | 01/01/2020 |
Clexio Biosciences Ltd.
 Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Direttore/Membro del Consiglio | 01/01/2018 |
8400 - The Health Network
 8400 - The Health Network Miscellaneous Commercial ServicesCommercial Services The private company is based in Raanana, Israel. It comprises a collective of around 400 healthtech leaders from academia, industry, government, healthcare organizations, and NGOs who collaborate to accelerate healthcare innovation, commercialization, and ecosystem development. Key initiatives include the 8400 leadership program, an intensive fellowship developed with partners such as Harvard Business School Executive Education and Israeli government bodies, designed to cultivate healthtech leadership and foster collaborations. Graduates become active network members engaged in national programs and ecosystem growth projects. The network operates a programs incubator focusing on six critical clusters—talent and skills, infrastructure and resources, funding, policy and regulation, tech transfer, and multinationals and network—to address ecosystem gaps and leverage opportunities. Projects include HealthIL, which has facilitated pilots bridging healthcare and technology, and the Israeli FHIR community (FHIR-IL), promoting standardized healthcare data exchange. 8400 also leads bi-national efforts and initiatives supporting venture formation, commercialization, and cross-border collaboration between Israeli and healthtech sectors. 8400 - The Health Network is an organization founded in 2017 dedicated to advancing Israel’s healthtech and life sciences industry as a major engine for economic growth and health innovation. | Direttore/Membro del Consiglio | 01/01/2019 |
Dexcel Ltd.
 Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Investitore di Private Equity | - |
Precedenti posizioni note di Ilan Oren
| Società | Posizione | Fine |
|---|---|---|
| SIO GENE THERAPIES INC. | Direttore/Membro del Consiglio | 24/09/2020 |
| SIO GENE THERAPIES INC. | Direttore/Membro del Consiglio | 21/12/2017 |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
Formazione di Ilan Oren
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
62
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
Dexcel Ltd.
Dexcel Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets generic pharmaceuticals | Health Technology |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes generic pharmaceuticals products | Health Technology |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Clexio Biosciences Ltd.
Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Develops novel therapies for patients suffering from neurological and psychiatric conditions | Health Technology |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing gene therapies for treatment of chronic diseases | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
8400 - The Health Network
8400 - The Health Network Miscellaneous Commercial ServicesCommercial Services The private company is based in Raanana, Israel. It comprises a collective of around 400 healthtech leaders from academia, industry, government, healthcare organizations, and NGOs who collaborate to accelerate healthcare innovation, commercialization, and ecosystem development. Key initiatives include the 8400 leadership program, an intensive fellowship developed with partners such as Harvard Business School Executive Education and Israeli government bodies, designed to cultivate healthtech leadership and foster collaborations. Graduates become active network members engaged in national programs and ecosystem growth projects. The network operates a programs incubator focusing on six critical clusters—talent and skills, infrastructure and resources, funding, policy and regulation, tech transfer, and multinationals and network—to address ecosystem gaps and leverage opportunities. Projects include HealthIL, which has facilitated pilots bridging healthcare and technology, and the Israeli FHIR community (FHIR-IL), promoting standardized healthcare data exchange. 8400 also leads bi-national efforts and initiatives supporting venture formation, commercialization, and cross-border collaboration between Israeli and healthtech sectors. 8400 - The Health Network is an organization founded in 2017 dedicated to advancing Israel’s healthtech and life sciences industry as a major engine for economic growth and health innovation. | Commercial Services |
